France Leads Europe In Reimbursing Truvada For HIV Prophylaxis
This article was originally published in Scrip
Gilead Sciences' HIV drug Truvada is now being reimbursed in France for pre-exposure prophylaxis (PrEP) under a "temporary use recommendation" (RTU) that came into effect on Jan. 4. This is understood to be the first European country where Truvada can be officially prescribed and reimbursed for PrEP, an indication for which it has not yet received an EU marketing authorization.
Register for our free email digests: